tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2024 Sep 25;11(10)
fae545.
doi: 10.1093/ofid/ofae545. eCollection 2024 Oct. Symptoms Six Weeks After COVID-19 Are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021-April 2022
Nicholas M Mohr[SUP] 1 [/SUP], Ian D Plumb[SUP] 2 [/SUP], Eliezer Santos León[SUP] 1 [/SUP], Malea Pinckney[SUP] 3 [/SUP], Karisa K Harland[SUP] 1 [/SUP], Anusha Krishnadasan[SUP] 4 [/SUP], Karin F Hoth[SUP] 1 [/SUP], Fernand Rwamwejo[SUP] 5 [/SUP], John P Haran[SUP] 6 [/SUP], Melissa Briggs-Hagen[SUP] 2 [/SUP], Eric Kontowicz[SUP] 1 [/SUP], David A Talan[SUP] 1 4 [/SUP]; Project PREVENT Network
Collaborators, Affiliations
Background: The objective of this study was to test the hypothesis that subsequent doses of the coronavirus disease 2019 (COVID-19) vaccine are associated with lower incidence of COVID-19-like symptoms at 6 weeks after infection.
Methods: This study was a case-control analysis of health care personnel in an ongoing multicenter COVID-19 vaccine effectiveness study. We enrolled participants at the time of COVID-19-like symptoms between December 19, 2021, and April 27, 2022, which corresponded to the early Omicron-predominant period after original monovalent severe acute respiratory syndrome coronavirus 2 additional vaccination doses became available. Our outcome was self-reported symptoms completed 6 weeks after the onset of symptoms.
Results: We enrolled 2478 participants, of whom 1422 (57%) had COVID-19. The prevalence of symptoms at 6 weeks was 26% (n = 373) in those with COVID-19 and 18% (n = 195) in those without COVID-19. Fatigue (11%) and difficulty sleeping (7%) were most strongly associated with COVID-19. A total of 1643 (66%) participants received a subsequent vaccine dose (after the primary series). Participants with COVID-19 who had received a subsequent vaccination had lower odds of symptoms at 6 weeks (adjusted odds ratio [aOR], 0.55; 95% CI, 0.43-0.70), but this relationship was not observed in those without COVID-19 (aOR, 0.87; 95% CI, 0.59-1.29).
Conclusions: Health care personnel who received subsequent doses of original monovalent COVID-19 vaccine had a lower prevalence of symptoms at 6 weeks than those that did not.
Keywords: COVID-19; COVID-19 vaccines; post-acute COVID-19 syndrome; vaccine efficacy.
. 2024 Sep 25;11(10)
fae545.doi: 10.1093/ofid/ofae545. eCollection 2024 Oct. Symptoms Six Weeks After COVID-19 Are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021-April 2022
Nicholas M Mohr[SUP] 1 [/SUP], Ian D Plumb[SUP] 2 [/SUP], Eliezer Santos León[SUP] 1 [/SUP], Malea Pinckney[SUP] 3 [/SUP], Karisa K Harland[SUP] 1 [/SUP], Anusha Krishnadasan[SUP] 4 [/SUP], Karin F Hoth[SUP] 1 [/SUP], Fernand Rwamwejo[SUP] 5 [/SUP], John P Haran[SUP] 6 [/SUP], Melissa Briggs-Hagen[SUP] 2 [/SUP], Eric Kontowicz[SUP] 1 [/SUP], David A Talan[SUP] 1 4 [/SUP]; Project PREVENT Network
Collaborators, Affiliations
- PMID: 39416989
- PMCID: PMC11481461
- DOI: 10.1093/ofid/ofae545
Background: The objective of this study was to test the hypothesis that subsequent doses of the coronavirus disease 2019 (COVID-19) vaccine are associated with lower incidence of COVID-19-like symptoms at 6 weeks after infection.
Methods: This study was a case-control analysis of health care personnel in an ongoing multicenter COVID-19 vaccine effectiveness study. We enrolled participants at the time of COVID-19-like symptoms between December 19, 2021, and April 27, 2022, which corresponded to the early Omicron-predominant period after original monovalent severe acute respiratory syndrome coronavirus 2 additional vaccination doses became available. Our outcome was self-reported symptoms completed 6 weeks after the onset of symptoms.
Results: We enrolled 2478 participants, of whom 1422 (57%) had COVID-19. The prevalence of symptoms at 6 weeks was 26% (n = 373) in those with COVID-19 and 18% (n = 195) in those without COVID-19. Fatigue (11%) and difficulty sleeping (7%) were most strongly associated with COVID-19. A total of 1643 (66%) participants received a subsequent vaccine dose (after the primary series). Participants with COVID-19 who had received a subsequent vaccination had lower odds of symptoms at 6 weeks (adjusted odds ratio [aOR], 0.55; 95% CI, 0.43-0.70), but this relationship was not observed in those without COVID-19 (aOR, 0.87; 95% CI, 0.59-1.29).
Conclusions: Health care personnel who received subsequent doses of original monovalent COVID-19 vaccine had a lower prevalence of symptoms at 6 weeks than those that did not.
Keywords: COVID-19; COVID-19 vaccines; post-acute COVID-19 syndrome; vaccine efficacy.